Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of LY4226695 in Healthy Participants
Sponsor: Eli Lilly and Company
Summary
The main purpose of this study is to assess how well LY4226695 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant in Parts A \& D, the study will last about 64 days and will include a stay in the Clinical Research Unit (CRU) lasting at most 7 days. For each participant in Parts B \& C, the study will last about 92 days and will include 5 stays in the CRU with each visit lasting at most 7 days.
Official title: A Single-ascending and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4226695 in Healthy Participants
Key Details
Gender
All
Age Range
22 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
148
Start Date
2026-08
Completion Date
2027-07
Last Updated
2026-08-17
Healthy Volunteers
Yes
Conditions
Interventions
LY4226695
Administered SC
LY4226695
Administered IV
Placebo
Administered SC
Locations (2)
CenExel ACT
Anaheim, California, United States
Lilly Centre for Clinical Pharmacology
Singapore, Singapore